Abstract:Abstract BACKGROUND Treatment decisions for patients with ulcerative colitis (UC) depend on the disease severity. This observational, cross-sectional, web-based survey sought to provide insight into the real-world symptoms and clinical characteristics that factor into healthcare providers’ (HCPs) treatment choices for their patients with UC in the United States. METHODS Self-reported data were collected from HCPs using a standard web-based questionnaire between 21 November 2022 and 6 December 2022. Eligible HCPs were required to have treated at least 10 adult patients with UC per month, worked more than 20 hours per week in direct patient care; and be able to complete the survey in English. HCPs included gastroenterologists (GIs), primary care physicians (PCPs), internal medicine (IM) or family medicine (FM) physicians, nurse practitioners (NPs), or physician assistants (PAs). Questionnaire responses were summarized through descriptive statistics, and post hoc comparisons between HCP types (GIs, FM/IM/PCPs, PAs, NPs) were performed using binomial regression models without adjustment for multiple comparisons. RESULTS Among 459 HCPs (male: 47.9%; 30-49 years age-group: 55.1%), 55.3% were physicians, 22.7% were NPs, and 22.0% were PAs. Approximately, 50% of the HCPs described their primary medical specialty as primary care/family care, followed by 37.7% in gastroenterology, and 12.9% in IM. From a list of 13 symptoms, when asked to select three symptoms they considered most important in deciding a course of treatment for UC, HCPs chose rectal bleeding (60%), followed by cramping or other abdominal pain (45%), diarrhea (41%), anemia (34%), and bowel urgency (28%, Fig. 1). The proportions were similar across HCP types except a greater proportion of GIs (60%) selected diarrhea than the other specialties (NPs: 42%, P=0.0127; FM/IM/PCPs: 33%, P<0.0001; PAs: 32%, P<0.0001). Rectal bleeding (87.4%), clinical remission (86.7%), abdominal pain (81.4%), stool frequency (77.6%), bowel urgency (77.3%), mucosal appearance (72.9%), and histologic appearance (71.5%) were rated as “very important” or “extremely important” by HCPs for deciding treatment choices (Fig. 2). A higher percentage of GIs, PAs, and NPs rated several symptoms more frequently vs FM/IM/PCPs, including bowel urgency (GIs: P<0.0001; PAs: P=0.0182; NPs: P=0.0342), mucosal appearance (P<0.0001, P=0.0091; P=0.0009), and stool frequency (P=0.0013; P=0.0283; P=0.0114) as “very important” or “extremely important.” CONCLUSION Results suggest a need for education among some specialties, particularly FMs, IMs, and PCPs, about the clinical presentation of UC and most important symptoms to consider when deciding treatment options for patients with UC. Fig. 1 Most important ulcerative colitis symptoms healthcare providers selected when deciding on a patient’s course of treatment Fig. 2 The level of importance assigned by the healthcare providers to the symptoms when deciding on the course of treatment for the patients with ulcerative colitis

P151 Assessing comprehensive remission for Ulcerative Colitis in clinical practice: International consensus recommendations

Practical management of mild-to-moderate ulcerative colitis: an international expert consensus

A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)

Considering Histologic Remission in Ulcerative Colitis as a Long-Term Target

P254 Outcomes of endoscopic and histologic remission in ulcerative colitis under advanced therapy

Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement

Resolution of rectal bleeding by day 7 in acute severe ulcerative colitis is prognostic for post-discharge corticosteroid free clinical remission and endoscopic improvement

Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis—An Exploratory Study to Define Deep Remission

Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials

P600 Efficacy of different modalities of faecal microbiota transplantation to induce clinical remission in patients with ulcerative colitis: a systematic review and network meta-analysis

Impact of completely histological remission on reducing flare-ups in moderate-to-severe, biologics-experienced ulcerative colitis patients with endoscopic remission

P732 Lack of concordance between patient-reported, physician-reported and objective criteria-based identification of suboptimal control in IBD patients: IBD PODCAST study results

The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe

P772 Comprehensive disease control in patients with Ulcerative Colitis: refinement of a multi-component endpoint using data from the filgotinib SELECTION trial

Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study

Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements

IDENTIFICATION OF DISEASE SEVERITY DEFINITIONS FOR ULCERATIVE COLITIS AND CROHN’S DISEASE

P355 Exceeding treatment expectations in Crohn’s disease: transmural healing and a new definition of deep remission

REAL-WORLD EXPERIENCE AND PERSPECTIVES ON THE TREATMENT OF ULCERATIVE COLITIS: RESULTS FROM A HEALTHCARE PROVIDER SURVEY

Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach

Development and validation of the Ulcerative Colitis patient-reported outcomes signs and symptoms (UC-pro/SS) diary